{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:24:59Z","timestamp":1764937499748,"version":"build-2065373602"},"reference-count":100,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018956","name":"NIHR Cambridge Biomedical Research Centre","doi-asserted-by":"publisher","award":["BRC-1215-20014"],"award-info":[{"award-number":["BRC-1215-20014"]}],"id":[{"id":"10.13039\/501100018956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.berh.2022.101809","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T15:26:26Z","timestamp":1671809186000},"page":"101809","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Horizon scan: State-of-the-art therapeutics for psoriatic arthritis"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3013-2429","authenticated-orcid":false,"given":"Joseph","family":"Hutton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip","family":"Mease","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0600-4566","authenticated-orcid":false,"given":"Deepak","family":"Jadon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2022.101809_bib1","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2022.101809_bib2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.berh.2022.101809_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000588","article-title":"Real-world burden of comorbidities in US patients with psoriatic arthritis","volume":"3","author":"Shah","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.berh.2022.101809_bib4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/rheumatology\/ker216","article-title":"Work disability in psoriatic arthritis: a systematic review","volume":"51","author":"Tillett","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2022.101809_bib5","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1007\/s10067-021-05713-8","article-title":"Healthcare utilization and costs among patients with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 to 2020","volume":"40","author":"Merola","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2022.101809_bib6","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","article-title":"Psoriasis prevalence in adults in the United States","volume":"157","author":"Armstrong","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.berh.2022.101809_bib7","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2022.101809_bib8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s13063-021-05142-7","article-title":"Treating to target in psoriatic arthritis: assessing real-world outcomes and optimising therapeutic strategy for adults with psoriatic arthritis-study protocol for the Monitor-PSA study, a trials within cohorts study design","volume":"22","author":"Rombach","year":"2021","journal-title":"Trials"},{"key":"10.1016\/j.berh.2022.101809_bib9","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/annrheumdis-2012-202608","article-title":"Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis","volume":"72","author":"Tillett","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2022.101809_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2021.101693","article-title":"Unmet needs in psoriatic arthritis","volume":"35","author":"Ng","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.berh.2022.101809_bib11","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/S0140-6736(18)30949-8","article-title":"Clinical management of psoriatic arthritis","volume":"391","author":"van den Bosch","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2022.101809_bib12","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/rheumatology\/keg384","article-title":"A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience","volume":"42","author":"Kane","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2022.101809_bib13","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s10067-019-04446-z","article-title":"Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: results from a large multinational real-world study","volume":"38","author":"Alten","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2022.101809_bib14","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2022.101809_bib15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10067-017-3908-y","article-title":"Current concepts and unmet needs in psoriatic arthritis","volume":"37","author":"Mahmood","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2022.101809_bib16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40744-016-0029-z","article-title":"Psoriatic arthritis and burden of disease: patient perspectives from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey","volume":"3","author":"Kavanaugh","year":"2016","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.berh.2022.101809_bib17","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3899\/jrheum.140021","article-title":"High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease","volume":"41","author":"Haroon","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2022.101809_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0195123","article-title":"Obesity and response to anti-tumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"13","author":"Singh","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.berh.2022.101809_bib19","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/annrheumdis-2013-204448","article-title":"Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis","volume":"74","author":"Eder","year":"2015","journal-title":"Ann Rheum Dis"},{"year":"2010","series-title":"Management of obesity","author":"Intercollegiate","key":"10.1016\/j.berh.2022.101809_bib20"},{"key":"10.1016\/j.berh.2022.101809_bib21","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(16)31893-1","article-title":"Screening and brief intervention for obesity in primary care: a parallel, two-arm, randomised trial","volume":"388","author":"Aveyard","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2022.101809_bib22","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2022.101809_bib23","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/oby.21955","article-title":"Bariatric surgery and the incidence of psoriasis and psoriatic arthritis in the Swedish obese subjects study","volume":"25","author":"Maglio","year":"2017","journal-title":"Obesity"},{"key":"10.1016\/j.berh.2022.101809_bib24","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/2012.jama.11792","article-title":"Health care use during 20 years following bariatric surgery","volume":"308","author":"Neovius","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.berh.2022.101809_bib25","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-018-0746-0","article-title":"Novel therapeutics in psoriatic arthritis. What is in the pipeline?","volume":"20","author":"Elalouf","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.berh.2022.101809_bib26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/14656566.2021.2006184","article-title":"Current unmet needs and emerging novel pharmacotherapies in psoriatic arthritis","volume":"23","author":"Tahir","year":"2022","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.berh.2022.101809_bib27","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/rheumatology\/kex387","article-title":"Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis","volume":"57","author":"Stober","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2022.101809_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.151979","article-title":"Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - a nationwide cohort study from the DANBIO and DERMBIO registries","volume":"53","author":"Egeberg","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2022.101809_bib29","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/14712598.2018.1450385","article-title":"The comparative immunogenicity of biologic therapy and its clinical relevance in psoriatic arthritis: a systematic review of the literature","volume":"18","author":"Balsa","year":"2018","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.berh.2022.101809_bib30","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.40851","article-title":"Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2022.101809_bib31","first-page":"100","article-title":"Cycling or swap biologics and small molecules in psoriatic arthritis: observations from a real-life single center cohort","author":"Ariani","year":"2021","journal-title":"Medicine"},{"key":"10.1016\/j.berh.2022.101809_bib32","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","author":"Mills","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.berh.2022.101809_bib33","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/s41590-019-0514-y","article-title":"IL-17 receptor\u2013based signaling and implications for disease","volume":"20","author":"Li","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.berh.2022.101809_bib34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na{\\\"\\i}ve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2022.101809_bib35","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2022.101809_bib36","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/bjd.20413","article-title":"Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study","volume":"185","author":"Gottlieb","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.berh.2022.101809_bib37","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.berh.2022.101809_bib38","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0140-6736(19)33161-7","article-title":"Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial","volume":"395","author":"Ritchlin","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2022.101809_bib39","first-page":"72","article-title":"Bimekizumab treatment is associated with improvements in back pain and fatigue in patients with active psoriatic arthritis: 48-week results from a phase 2b study","author":"Deodhar","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2022.101809_bib40","first-page":"72","article-title":"Bimekizumab maintenance of response in patients with psoriatic arthritis: 2-year results from a phase 2b dose-ranging study and its open-label extension","author":"Merola","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2022.101809_bib41","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1136\/annrheumdis-2020-eular.1850","article-title":"SAT0403 efficacy and safety of 108 weeks bimekizumab treatment in patients with psoriatic arthritis: interim results from a phase 2 open-label extension study","volume":"79","author":"Mcinnes","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2022.101809_bib42","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/annrheumdis-2022-eular.5016","article-title":"LB0001 bimekizumab in bdmard-naive patients with psoriatic arthritis: 24-Week efficacy \\& safety from be optimal, a phase 3, multicentre, randomised, placebo-controlled, active reference study","volume":"81","author":"Mcinnes","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2022.101809_bib43","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1136\/annrheumdis-2022-eular.2265","article-title":"OP0255 bimekizumab in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: 16-Week efficacy \\& safety from be Complete, a phase 3, multicentre, randomised placebo-controlled study","volume":"81","author":"Merola","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2022.101809_bib44","unstructured":"A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (BE VITAL). Bethesda (MD): US National Library of Medicine n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04009499 (accessed September 14, 2022)."},{"key":"10.1016\/j.berh.2022.101809_bib45","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2019-216835","article-title":"Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2022.101809_bib46","first-page":"1","article-title":"The IL-17\/IL-23 Axis and its genetic contribution to psoriatic","volume":"11","author":"Vecellio","year":"2021","journal-title":"Arthritis"},{"key":"10.1016\/j.berh.2022.101809_bib47","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2022.101809_bib48","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2022.101809_bib49","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial","volume":"81","author":"Kristensen","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2022.101809_bib50","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial","volume":"81","author":"\u00d6st\u00f6r","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2022.101809_bib51","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/annrheumdis-2020-219014","article-title":"Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2022.101809_bib52","unstructured":"Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1). Bethesda (MD): US National Library of Medicine n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04314544 (accessed September 14, 2022)."},{"key":"10.1016\/j.berh.2022.101809_bib53","unstructured":"Efficacy and safety of tildrakizumab compared to placebo in anti-TNF na\u00efve subjects with active psoriatic arthritis II (INSPIRE 2). Bethesda (MD): US National Library of Medicine n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04314531 (accessed September 14, 2022)."},{"key":"10.1016\/j.berh.2022.101809_bib54","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/bjd.18232","article-title":"Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.berh.2022.101809_bib55","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/bjd.19866","article-title":"Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)","volume":"185","author":"Thaci","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.berh.2022.101809_bib56","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41584-019-0285-8","article-title":"Bedside to bench: defining the immunopathogenesis of psoriatic arthritis","volume":"15","author":"Bravo","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2022.101809_bib57","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2022.101809_bib58","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2022.101809_bib59","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001595","article-title":"Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure","volume":"7","author":"Burmester","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.berh.2022.101809_bib60","series-title":"Upadacitinib in patients with psoriatic arthritis and an inadequate response to biological therapy : 56- week data from the phase 3 SELECT- PsA 1 study","first-page":"1","author":"Mcinnes","year":"2021"},{"key":"10.1016\/j.berh.2022.101809_bib61","first-page":"312","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2022.101809_bib62","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2022.101809_bib63","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S2665-9913(21)00041-2","article-title":"Editorial JAK inhibitors : fate in doubt for rheumatoid arthritis","volume":"3","author":"Rheumatology","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.berh.2022.101809_bib64","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2022.101809_bib65","unstructured":"A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Na\u00efve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF\u03b1 Inhibitor Treatmen. Bethesda (MD): US National Library of Medicine n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04908189 (accessed September 15, 2022)."},{"key":"10.1016\/j.berh.2022.101809_bib66","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","author":"Armstrong","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.berh.2022.101809_bib67","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial","author":"Strober","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.berh.2022.101809_bib68","article-title":"Efficacy and safety of brepocitinib (tyrosine kinase 2\/janus kinase 1 inhibitor) for the treatment of active psoriatic arthritis: results from a phase 2b randomized controlled trial","volume":"73","author":"Mease","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2022.101809_bib69","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/0960327117715901","article-title":"Differential effect of p38 and MK2 kinase inhibitors on the inflammatory and toxicity biomarkers in vitro","volume":"37","author":"Singh","year":"2018","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.berh.2022.101809_bib70","article-title":"A novel MK2 inhibitor for the treatment of ankylosing spondylitis and other inflammatory diseases","volume":"71","author":"Ram\u00edrez-Valle","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2022.101809_bib71","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13075-022-02850-6","article-title":"CC-99677, a novel, oral, selective covalent MK2 inhibitor, sustainably reduces pro-inflammatory cytokine production","volume":"24","author":"Gaur","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2022.101809_bib72","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/art.24485","article-title":"Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies","volume":"60","author":"Damjanov","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2022.101809_bib73","first-page":"515","article-title":"p38 inhibition and not MK2 inhibition enhances the secretion of chemokines from TNF-alpha activated rheumatoid arthritis fibroblast-like synoviocytes","volume":"31","author":"Dulos","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2022.101809_bib74","first-page":"123","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the MK2 inhibitor ATI-450 in healthy subjects: a placebo-controlled, randomized phase 1 study","volume":"13","author":"Gordon","year":"2021","journal-title":"Clin Pharmacol"},{"year":"2022","series-title":"Study of ATI-450 vs placebo in patients with moderate to severe psoriatic arthritis","key":"10.1016\/j.berh.2022.101809_bib75"},{"year":"2021","series-title":"A study of CC-99677 in participants with active ankylosing spondylitis (AS SpA axSpA)","key":"10.1016\/j.berh.2022.101809_bib76"},{"key":"10.1016\/j.berh.2022.101809_bib77","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/annrheumdis-2022-eular.536","article-title":"OP0258 izokibep (ABY-035) in patients with active psoriatic arthritis \u2013 16-WEEK results from a phase 2 study","volume":"81","author":"Behrens","year":"2022","journal-title":"Ann Rheum Dis"},{"year":"2022","series-title":"Affibody. Affibody, ACELYRIN, and Inmagene biopharmaceuticals announce data from global phase 2 trial of izokibep in patients with psoriatic arthritis presented during 2022 European alliance of associations for rheumatology congress","key":"10.1016\/j.berh.2022.101809_bib78"},{"year":"2022","series-title":"Announces $300 million series C financing to accelerate phase 3 development of izokibep, a unique IL-17a inhibitor to treat inflammatory diseases","key":"10.1016\/j.berh.2022.101809_bib79"},{"key":"10.1016\/j.berh.2022.101809_bib80","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","article-title":"IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2022.101809_bib81","article-title":"GM-CSF expression and macrophage polarization in joints of undifferentiated arthritis patients evolving to rheumatoid arthritis or psoriatic arthritis","volume":"11","author":"Fuentelsaz-Romero","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2022.101809_bib82","doi-asserted-by":"crossref","first-page":"e677","DOI":"10.1016\/S2665-9913(20)30229-0","article-title":"Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study","volume":"2","author":"Buckley","year":"2020","journal-title":"Lancet Rheumatol"},{"year":"2022","series-title":"Efficacy and safety of GSK3196165 versus placebo and tofacitinib in participants with moderately to severely active rheumatoid arthritis who have an inadequate response to methotrexate (contRAst 1)","key":"10.1016\/j.berh.2022.101809_bib83"},{"year":"2022","series-title":"Efficacy and safety of GSK3196165 versus placebo and tofacitinib in participants with moderately to severely active rheumatoid arthritis who have an inadequate response to conventional synthetic (cs)\/Biologic (b) disease modifying anti-rheumatic drugs","key":"10.1016\/j.berh.2022.101809_bib84"},{"year":"2022","series-title":"Efficacy and safety of GSK3196165 (otilimab) versus placebo and sarilumab in participants with moderately to severely active rheumatoid arthritis who have an inadequate response to biological disease-modifying antirheumatic drug (DMARDs) and\/or janus kina","key":"10.1016\/j.berh.2022.101809_bib85"},{"year":"2022","series-title":"Long-term safety and efficacy of GSK3196165 (otilimab) in the treatment of rheumatoid arthritis (RA) (contRAst X)","key":"10.1016\/j.berh.2022.101809_bib86"},{"key":"10.1016\/j.berh.2022.101809_bib87","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/annrheumdis-2021-eular.221","article-title":"OP0115 efficacy and safety of ABBV-3373, a novel anti-tnf glucocorticoid receptor modulator antibody drug conjugate, in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy: a phase 2A proof of concept study","volume":"80","author":"Buttgereit","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2022.101809_bib88","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/art.40579","article-title":"Phase II study of ABT-122, a tumor necrosis factor\u2013 and interleukin-17a\u2013targeted dual variable domain immunoglobulin, in patients with psoriatic arthritis with an inadequate response to methotrexate","volume":"70","author":"Mease","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2022.101809_bib89","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/art.40580","article-title":"ABT-122, a bispecific dual variable domain immunoglobulin targeting tumor necrosis factor and interleukin-17a, in patients with rheumatoid arthritis with an inadequate response to methotrexate","volume":"70","author":"Genovese","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2022.101809_bib90","article-title":"TI - dual blockad I-F. Dual blockade of TNF and IL-17a inhibits inflammation and structural damage in a rat model of spondyloarthritis","volume":"23","author":"Au - Bryant","year":"2022","journal-title":"Int J Mol Sci"},{"year":"2022","series-title":"A study of guselkumab and golimumab combination therapy in participants with active psoriatic arthritis (AFFINITY)","key":"10.1016\/j.berh.2022.101809_bib91"},{"key":"10.1016\/j.berh.2022.101809_bib92","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41584-018-0042-4","article-title":"Leukocyte trafficking between stromal compartments: lessons from rheumatoid arthritis","volume":"14","author":"Buckley","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2022.101809_bib93","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrrheum.2015.157","article-title":"Successes and failures of chemokine-pathway targeting in rheumatoid arthritis","volume":"12","author":"Szekanecz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2022.101809_bib94","first-page":"275","article-title":"Natalizumab in the treatment of Crohn's disease","volume":"2","author":"Guagnozzi","year":"2008","journal-title":"Biologics"},{"key":"10.1016\/j.berh.2022.101809_bib95","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2022.101809_bib96","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2022.101809_bib97","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/key440","article-title":"Vedolizumab for inflammatory bowel disease: a two-edge sword in the gut-joint\/enthesis axis","volume":"58","author":"Garc\u00eda-Vicu\u00f1a","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2022.101809_bib98","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41591-020-0939-8","article-title":"Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis","volume":"26","author":"Alivernini","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.berh.2022.101809_bib99","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41586-019-1263-7","article-title":"Distinct fibroblast subsets drive inflammation and damage in arthritis","volume":"570","author":"Croft","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.berh.2022.101809_bib100","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/rheumatology\/key069","article-title":"Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis","volume":"58","author":"Miyagawa","year":"2019","journal-title":"Rheumatology"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694222000687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694222000687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:23:31Z","timestamp":1761499411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694222000687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1521694222000687"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2022.101809","relation":{},"ISSN":["1521-6942"],"issn-type":[{"type":"print","value":"1521-6942"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Horizon scan: State-of-the-art therapeutics for psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2022.101809","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101809"}}